Ken Griffin Merus N.V. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$47.19 - $58.84 $495,495 - $617,820	-10,500 Reduced 31.07%	23,300 $1.16 Million
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $87,582 - $132,440	2,200 Added 6.96%	33,800 $2 Million
Q1 2024 May 15, 2024	BUY	$28.03 - $51.82 $857,718 - $1.59 Million	30,600 Added 3060.0%	31,600 $1.42 Million
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $66,198 - $94,578	-3,300 Reduced 76.74%	1,000 $27,000
Q3 2023 Nov 14, 2023	SELL	$20.13 - $27.29 $305,976 - $414,808	-15,200 Reduced 77.95%	4,300 $101,000
Q2 2023 Aug 14, 2023	BUY	$18.33 - $27.18 $260,285 - $385,956	14,200 Added 267.92%	19,500 $513,000
Q1 2023 May 15, 2023	SELL	$14.25 - $20.5 $292,125 - $420,250	-20,500 Reduced 79.46%	5,300 $97,000
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $330,240 - $610,428	25,800 New	25,800 $399,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.92B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.